Yang Yong-Xiao, Li Qin, Li Wei-Dong, Wang Tian-Yun, Feng Hui-Gen
Department of Life Science and Technology, Xinxiang Medical University, Xinxiang, 453003, Henan, China.
Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Curr Pharm Biotechnol. 2023;24(3):391-400. doi: 10.2174/1389201023666220603121316.
The market demand for recombinant therapeutic proteins (RTPs) has promoted the development of various protein expression host and bioprocessing technologies. Since mammalian cells have the unique advantage of being able to direct the correct folding of proteins and provide post-translational processing such as complex glycosylation, the RTPs produced by them currently account for approximately 80% of the approved marketed RTPs. Among them, Chinese hamster ovary (CHO) cells are currently the preferred host cells for the production of RTPs. Production of RTPs in CHO cells involves the synthesis, processing, transport, and secretion of proteins. The secretion process of proteins is one of the key steps, which greatly limits the yield and quality of RTPs. Here, we review the recombinant protein secretion process of CHO cells and its influencing factors, and further discuss the optimization strategy for recombinant protein secretion and expression in CHO cells.
重组治疗性蛋白(RTPs)的市场需求推动了各种蛋白质表达宿主和生物加工技术的发展。由于哺乳动物细胞具有能够指导蛋白质正确折叠并提供翻译后加工(如复杂糖基化)的独特优势,目前它们生产的RTPs约占已批准上市的RTPs的80%。其中,中国仓鼠卵巢(CHO)细胞是目前生产RTPs的首选宿主细胞。在CHO细胞中生产RTPs涉及蛋白质的合成、加工、运输和分泌。蛋白质的分泌过程是关键步骤之一,这极大地限制了RTPs的产量和质量。在此,我们综述了CHO细胞的重组蛋白分泌过程及其影响因素,并进一步讨论了CHO细胞中重组蛋白分泌和表达的优化策略。